PDF
MORRIS PLAINS, N.J., July 18, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Biologics License Application (BLA) for filing and granted Priority Review for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who previously received at least two prior therapies for metastatic disease. The PDUFA target action date is January 18, 2019. If approved, sacituzumab govitecan would be the first and only ADC approved for the treatment of mTNBC. “We are delighted that the FDA has accepted the sacituzumab govitecan BLA for Priority Review,” commented Michael Pehl, President and Chief Executive Officer. “We will continue to work closely with the regulatory agency as we strive to bring this potential new treatment to mTNBC p[Read more]

IMPACT SNAPSHOT

EVENT TIME:

IMMU

Last Price

Price Change

Price Change %

Volume Shares

Max Up

Max Down

Volume Ratio

%

Performance comparisonUpdated

EVENT DAY

Stock performance from the time of news release until the following 4pm ET market close

LAST PRICE AT NEWS EVENT

SINCE EVENT

Multi-day stock performance from the time of the news release

EVENT DAY

Stock performance from the time of news release until the following 4pm ET market close

LAST PRICE AT NEWS EVENT

SINCE EVENT

Multi-day stock performance from the time of the news release

LAST PRICE

VWAP

High:

MAX UP

High:

Low:

MAX DOWN

Low:

%

POST NEWS RANGE

%

PRICE CHANGE

PRICE CHANGE PERCENTAGE

S&P 500 (SPX)

%

VOLUME RATIO

%

VOLUME (SHARES)

TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move

via News Quantified

CLICK TO SHARE:

EVENT DAY

Event Day Chart will not be displayed beyond 90-day period of the event

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know
exactly what the average effect will be on a particular stock.

Copyright Ⓒ News Quanitifed LLC 2012-2018, All product trademarks, names, logos, and brands are property of their respective owners. Image(s) or Footage (as applicable), used under license from Shutterstock.com.1.1.5

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.